Cargando…

Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine

Detalles Bibliográficos
Autores principales:	Holzworth, Amy, Couchot, Patrick, Cruz-Knight, Wanda, Brucculeri, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Society of Nephrology. Published by Elsevier Inc. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149162/ https://www.ncbi.nlm.nih.gov/pubmed/34048824 http://dx.doi.org/10.1016/j.kint.2021.05.007

Ejemplares similares

De novo vasculitis after mRNA-1273 (Moderna) vaccination
por: Anderegg, Manuel A., et al.
Publicado: (2021)

Bullous Pemphigoid Following the Moderna mRNA-1273 Vaccine
por: Desai, Amar D, et al.
Publicado: (2022)

Re: Heterologous Gam-COVID-Vac (Sputnik V)/mRNA-1273 (Moderna) vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination
por: Channa, Leelakrishna, et al.
Publicado: (2021)

Comparison of BNT162b2 (Pfizer–BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients
por: Kaiser, Robert A., et al.
Publicado: (2021)

Heterologous Gam-COVID-Vac (Sputnik V)/mRNA-1273 (Moderna) vaccination: Author's response
por: Pereson, Matías J., et al.
Publicado: (2022)

Central retinal artery occlusion after Moderna mRNA-1273 vaccination
por: Chow, Sin Yu, et al.
Publicado: (2022)

Immune Thrombocytopenia Following Booster Dose of the Moderna mRNA-1273 Vaccine
por: Breetz, Katherine A, et al.
Publicado: (2022)

Parsonage Turner Syndrome Following Vaccination With mRNA-1273 SARS-CoV-2 Vaccine
por: Bernheimer, James H., et al.
Publicado: (2022)

Small-Fiber Neuropathy After Vaccination With mRNA-1273 SARS-CoV-2 Vaccine
por: Bernheimer, James H., et al.
Publicado: (2023)

Humoral response of the mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients
por: Rodríguez-Espinosa, Diana, et al.
Publicado: (2021)

Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine
por: Malayala, Srikrishna V, et al.
Publicado: (2021)

New‐onset vitiligo following mRNA‐1273 (Moderna) COVID‐19 vaccination
por: Kaminetsky, Joshua, et al.
Publicado: (2021)

Pityriasis rosea after Moderna mRNA‐1273 vaccine: A case series
por: Martora, Fabrizio, et al.
Publicado: (2021)

Sensitization to trometamol in patients with delayed local reactions after administration of the Moderna mRNA-1273 vaccine against SARS-CoV-2
por: Davila-Fernandez, Galicia, et al.
Publicado: (2022)

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
por: Baden, Lindsey R., et al.
Publicado: (2020)

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
por: Ali, Kashif, et al.
Publicado: (2021)

Bell's palsy as a possible complication of mRNA-1273 (Moderna) vaccine against COVID-19
por: Poudel, Sujan, et al.
Publicado: (2022)

Acquired Angioedema Acute Attack After Administration of the Moderna COVID-19 (mRNA-1273) Vaccine
por: Graziani, Alessandro, et al.
Publicado: (2023)

2336. General Safety Profile of mRNA-1273 (Moderna COVID-19 Vaccine) in the Elderly Population
por: Anteyi, Kate, et al.
Publicado: (2023)

Covid-19 vaccine management (Comirnaty and mrna-1273 Moderna) in a teaching hospital in Italy: a short report on the vaccination campaign
por: Papini, Francesca, et al.
Publicado: (2021)

A de novo case of minimal change disease following the first dose of the Moderna mRNA-1273 SARS-CoV-2 vaccine without relapse after the second dose
por: Mochizuki, Reika Ikegami, et al.
Publicado: (2022)

Antibodies against SARS-CoV-2 Alpha, Beta, and Gamma Variants in Pregnant Women and Their Neonates under Antenatal Vaccination with Moderna (mRNA-1273) Vaccine
por: Chen, Wei-Chun, et al.
Publicado: (2022)

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
por: Widge, Alicia T., et al.
Publicado: (2020)

Immunogenicity of Sars-Cov-2 mRNA 1273 Vaccine in Patients with Lymphoid Malignancies
por: Dong, Ning, et al.
Publicado: (2021)

Acute Myocarditis Following mRNA-1273 SARS-CoV-2 Vaccination
por: Williams, Curtis B., et al.
Publicado: (2021)

Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report
por: Hasnie, Ammar A., et al.
Publicado: (2021)

Acute tolerance of Moderna mRNA-1273 vaccine against COVID-19 in patients with cancer treated with radiotherapy
por: Scoccianti, Silvia, et al.
Publicado: (2021)

Guillain‐Barré syndrome after mRNA‐1273 (Moderna) COVID‐19 vaccination: A case report
por: Anjum, Zauraiz, et al.
Publicado: (2022)

Paucisymptomatic COVID-19 in lung transplant recipient following two doses of mRNA-1273 (Moderna) vaccine
por: Marinelli, Tina, et al.
Publicado: (2021)

Cutaneous Sarcoidosis-like Eruption Following Second Dose of Moderna mRNA-1273 Vaccine: Case or Relationship?
por: Cazzato, Gerardo, et al.
Publicado: (2023)

2357. Descriptive Analyses of mRNA-1273 (Moderna COVID-19 vaccine) Spontaneous Reports by Geographic Regions
por: Emile-Backer, Magalie, et al.
Publicado: (2023)

Assessment of the humoral response to the homologous Gam-COVID-Vac (Sputnik V) or heterologous Sputnik V/mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in dialysis patients
por: Laham, Gustavo, et al.
Publicado: (2022)

Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions
por: Haq, Hannah N., et al.
Publicado: (2022)

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
por: Corbett, Kizzmekia S., et al.
Publicado: (2020)

Large inter-individual variability of cellular and humoral immunological responses to mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in health care workers
por: Krüttgen, Alexander, et al.
Publicado: (2022)

SARS-CoV-2 IgG spike protein antibody response in mRNA-1273 Moderna(®) vaccinated patients on maintenance immunoapheresis – a cohort study
por: Gaggl, Martina, et al.
Publicado: (2022)

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
por: Anderson, Evan J., et al.
Publicado: (2020)

A short discussion about the SARS-CoV-2 mRNA-1273 vaccine
por: Oronsky, Bryan, et al.
Publicado: (2021)

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
por: El Sahly, Hana M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t7mi7c8msrh5l3p6r56chjmuku